It can be relatively easy to experience medical benefits from cannabis. A puff or two of tetrahydrocannabinol (THC)-rich flower can do the trick for a lot of people.
Many health professionals have little to no experience with cannabis therapeutics and are not able to guide people on this subject. So Project CBD has created a beginner’s guide to cannabidiol & cannabis therapeutics to address key questions of CBD users.
Although it may not be obvious during these Trump-rattled times, we’re in the midst of a psychedelic revival. There is more interest than ever before in experimenting with LSD, magic mushrooms, ayahuasca, ketamine, and other psychedelic drugs.
The interactions between plant cannabinoids and a drug-metabolizing enzyme called carboxylesterase 1 (CES1) was recently published in Drug Metabolism and Distribution. Researchers at the Universities of Michigan and Florida showed that THC, CBD, and cannabinol (CBN) all inhibit CES1. CES1 is important for activating or inactivating drugs that regulate blood pressure, as well as the ADD drug Ritalin.
The kidneys are a workhorse of the body, filtering nutrients from toxins. Oily cannabinoids like THC and CBD slip out of the kidneys’ filtration system, but they stop to interact with cannabinoid receptors that regulate kidney function. Researchers in British Columbia review information about cannabis use in patients with chronic kidney disease (CKD).
It’s no secret that many cancer patients are using cannabis to help manage pain, fatigue, nausea, and other side effects of chemotherapy. Less well known is the fact that extensive preclinical research shows that plant cannabinoids — most notably, tetrahydrocannabinol (THC) and cannabidiol (CBD) – produce antitumor responses in various animal models of cancer.
Breast cancers are often classified by the receptors they express. The three most common breast cancer receptors respond to estrogen, progesterone, or epidermal growth factor. The latter include HER2-positive breast cancers. Identifying these receptors facilitates treatment. A study led by scientists in Spain indicates that the endocannabinoid system plays an important role in the treatment of HER2-positive cancer.
The first medical use of THC allowed by the FDA was the 1985 approval of isolate THC (Marinol) to treat nausea and vomiting from chemotherapy. Since then, research has demonstrated numerous possible applications of THC and cannabis in cancer patients, including painkilling, protecting the brain from toxic chemo, and even synergizing with the treatment itself.
In clinical research, cannabis is often set up to fail. Federal restrictions privilege studying isolated molecules from cannabis over the plant itself. And even when cannabis research is done, scientists are often forced to use low-quality weed from the National Institute of Drug Abuse. Because of this, most of the useful medical data on cannabis comes from observational studies, where people consuming cannabis are asked about their experience. Researchers in Albuquerque recently analyzed an app-based survey of over 3,000 cannabis users.